Tarsus Pharmaceuticals, Inc. (TARS): Capital Expenditures
$9.86M
Year ended 2025-12-31
$18.16M
Trailing 12 months to 2026-06-30
+169.1%
3-year compound annual growth
+84.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.86M | +529.2% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $1.57M | +4.3% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $1.50M | +196.8% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $506.0K | -13.7% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $586.0K | +28.5% | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | $456.0K | +160.6% | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | $175.0K | n/a | 2021-03-31, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $9.86M | +529.2% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $4.34M | -16.1% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $22.57M | +174.4% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $11.95M | +182.0% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $28.00M | +451.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $2.96M | -19.2% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.16M | -57.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $33.84M | +205.7% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗